Trial Profile
Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2012
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sanofi
- 13 Feb 2009 New source identified and integrated (ClinicalTrials.gov record NCT00845429). Status changed from recruiting to completed
- 06 Jun 2008 New trial record.